BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start

Core Viewpoint - BioVersys AG has received confirmation from the US FDA to proceed with the global Phase 3 pivotal trial for BV100, targeting serious infections caused by multi-drug resistant bacteria, specifically carbapenem-resistant Acinetobacter baumannii [1][6]. Company Overview - BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products for life-threatening infections caused by multi-drug resistant bacteria [11]. - The company operates from Basel, Switzerland, and utilizes two internal technology platforms to develop treatments that address high unmet medical needs in antimicrobial and microbiome fields [11]. Product Development - BV100 is a novel intravenous formulation of rifabutin designed to treat infections caused by Acinetobacter baumannii, including carbapenem-resistant strains [2][9]. - BV100 has received Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA, allowing for priority review and a five-year market exclusivity extension upon approval [2][9]. Clinical Trials - The Phase 3 trial (RIV-TARGET) will evaluate the efficacy and safety of BV100 combined with low-dose polymyxin B in patients with hospital-acquired or ventilator-associated bacterial pneumonia due to CRABC [4][5]. - Approximately 300 patients will be enrolled in the pivotal trial, with a primary efficacy endpoint of 28-day all-cause mortality [4]. - A successful Phase 2 trial demonstrated a 50% relative reduction in 28-day all-cause mortality compared to best available therapy, indicating a significant survival benefit [7]. Future Plans - The global Phase 3 trial is expected to read out by the end of 2027, with subsequent regulatory submissions planned for 2028 in the US, Europe, and China [6][7]. - An open-label Phase 2b differentiation trial (RIV-CARE) will also be initiated to provide real-world evidence of clinical practices in high drug resistance settings, with interim analysis planned for the end of 2026 [8].